Carcinoma EsophagusPresented By:Dr. VandanaDept. of Radiation OncologyCSMMU, Lucknow
Clinical Anatomy„ Hollow muscular tube 25 cm in  length which spans from the  cricopharyngeus at the cricoid  cartilage to...
Contd…Four regions of the esophagus:„    Cervical = cricoid cartilage to    thoracic inlet (15–18 cm from    the incisor)....
Lymphatic Drainage„   Rich mucosal and submucosal    lymphatic system.„   The submucosal lymphatics may    extend long dis...
Epidemiology„   Esophageal cancer is the 7th leading cause of cancer deaths.„   accounts for 1% of all malignancy & 6% of ...
Contd…„ Worldwide SCC responsible for most of the cases.„    Adenocarcinoma now accounts for over 50% of esophageal cancer...
Risk Factors : Squamous Cell Carcinoma„   Smoking and alcohol (80% - 90%)„   Dietary factors     ƒ   N-nitroso compounds (...
Risk Factors: Adenocarcinoma„ Associated with Barretts’s esophagus, GERD  & hiatal hernia.„ Obesity (3 to 4 fold risk)„ Sm...
Pattern of spread„    No serosal covering, direct invasion of contiguous structures occurs early.„    Commonly spread by l...
Site-wise nodal involvement
Pathological Classification                        95%
Clinical Features„ It is commonly associated with the  symptoms of dysphagia, wt. loss, pain,  anorexia, and vomiting„ Sym...
Contd…Complications:„ Cachexia, Malnutrition, dehydration, anaemia,.„ Aspiration pneumonia.„ Distant metastasis.„ Invasion...
AJCC TNM classification                          „   a:     Includes     nodes                              previously   l...
Staging : Squamous cell carcinoma
Staging : AdenocarcinomaGroup       T         N     M    Grade 0       Tis (HGD)                1, X IA         T1        ...
Diagnostic Workup„        Detailed history & Physical examination: Dysphagia,    odynophagia, hoarseness, wt. loss, use of...
„ Staging:    ƒ    CT chest and abdomen: Essential for staging because it can identify extension        beyond the esophag...
Endoscopic Ultrasonography„   EUS:    ƒ   assess the depth of penetration and LN involvement. Limited by the degree of    ...
PET Scan  „   most recently, proven to be valuable staging tool  „   can detect up to 15–20% of metastases not seen on CT ...
„ Barium swallow:   ƒ can delineate proximal and distal margins as well as TEF   ƒ Helpful for correlation with simulation...
Treatment
Management depends upon:„   Site of disease„   Extent of disease involvement„   Co-morbid conditions„   Patient preference.
Surgery„ Prerequisite for surgery    ƒ disease should be 5 cm beyond cricophyrangeus.„ Surgery indications    ƒ Lower 1/3 ...
Types of Surgery„   Transhiatal esophagectomy: for tumors anywhere in esophagus or    gastric cardia. No thoracotomy. Blun...
Chemotherapy„ No data proving that chemotherapy alone provides improved  survival or palliation. Partial response, not lon...
„ Platinum doublet is preferred over single agents„ Cisplatin plus 5-FU or docetaxel are commonly used combinationsRegimen...
Radiotherapy„ Curative  ƒ   Radical RT  ƒ   Pre-Op RT  ƒ   Post Op RT  ƒ   Concurrent chemo-radiation„ Palliative„ EBRT„ B...
EBRT Techniques„   Patient Positioning:    ƒ CERVICAL ESOPHAGUS: Supine with arms by the side    ƒ   MID AND LOWER THIRD: ...
EBRT – Cervical EsophagusField Portals:„ AP – PA foll. by opposed oblique pair.„ 2 anterior obliques and 1 posterior field...
EBRT – Mid & Lower1/3rd AP – PA followed by 1 Ant and 2 Post oblique pair 4 FIELD : AP-PA & opposed laterals – for mid 1...
Radiotherapy for CA esophagus
EBRT - DOSES„ Energy    ƒ   6 – 10 MV linac or Co60„ Chemoradiation:    ƒ 50.4 Gy in 28 # at 1.8 Gy per #    ƒ Boost to 60...
Brachytherapy (Intraluminal)„ As a boost after EBRT or as a palliative measure„ Local control of 25% - 35 in palliative se...
American Brachytherapy Society GuidelinesPatient selection:   ƒ    Primary tumor length ≤ 10 cm length   ƒ    Tumor confin...
Contd…„   EBRT 45 – 50 Gy in 1.8-2.0Gy /#,5#/wk         ‚   HDR – 5 Gy x two # one week apart , 2 – 3weeks after EBRT.    ...
APPLICATORS
Trials – RT alone„   No randomized trials of RT Vs Sx„   5 yr survival with conventional RT : < 10%„   Tumors < 5 cm , 5 y...
Contd…„ For cervical esophagus, cure rates were similar with Radical RT or  Sx alone.„ RT or Sx alone DOES NOT alter the n...
Trials– PreOP RT„ Principle:    ƒ  ↑ resectability, ↓ likelihood of tumor dissemination during Sx ,      ↑ radioresponsive...
Trials– PostOP RT„ Advantages:  ƒ  Treat areas at risk for recurrences while minimizing    dose to OAR.  ƒ Patients with n...
Contd…„    2 randomised trials:     ƒ Peniere et al :-         ‚   221 pts, mid / low 1/3rd growth         ‚   RT : 45- 55...
Trials– Chemoradiation                      ChemoRT Vs RT Alone„ RTOG 8501 INTERGROUP TRIAL:   ƒ 121 pts: 60 pts RT alone ...
Contd…             RT dose escalation in Chemo RT„   Intergroup 0123 TRIAL – 218 pts    ƒ Chemoradiation - either 50.4 Gy ...
Contd…               PRE OP CHEMO RT Vs Sx ALONE„ 44 Randomised trials„ 2 studies showed  in local recurrence   ƒ Urba et...
Pre-operative Chemotherapy                     The role of preoperative                     chemotherapy      alone     is...
Stage                                Recommended treatmentStage I–III and IVA      definitive chemo-RT (preferred for cerv...
Current approach„   EBRT using 3D-CRT to a total dose of 50.4 Gy (1.8 Gy per daily fraction) is    standard.„   IMRT is of...
Conclusion„    Esophageal cancer is the 7th leading cause of cancer deaths.„    Adenocarcinoma now accounts for over 50% o...
Thank You
ChemoRT followed Sx Vs.ChemoRT                      „   Patient undergoing surgery                          have worse qua...
Figure:    A     proposed    treatmentalgorithm for esophageal cancer.
Carcinoma oesophagus
Carcinoma oesophagus
Carcinoma oesophagus
Carcinoma oesophagus
Carcinoma oesophagus
Carcinoma oesophagus
Carcinoma oesophagus
Upcoming SlideShare
Loading in...5
×

Carcinoma oesophagus

11,450

Published on

this seminar provides details about carcinoma of oesophagus.

Prepared and Presented By Dr. Vandana.
Department of Radiotherapy, CSMMU, Lucknow

Published in: Health & Medicine
2 Comments
17 Likes
Statistics
Notes
No Downloads
Views
Total Views
11,450
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
1,714
Comments
2
Likes
17
Embeds 0
No embeds

No notes for slide
  • For cervical primaries, patients are placed supine. Various field designs are possible and their choice depends on the geometry of the primary tumor in relation to the spinal cord. The ideal design is a three-field technique (two anterior obliques and a posterior). However, since the primary tumor is rarely limited to the midline, the most common approach is anteroposterior (AP)/posteroanterior (PA) to 39.6 to 41.4 Gy (Fig. 36-3) followed by a left or right opposed oblique pair with photons to 50.4 Gy (Fig. 36-4A-C). Since this technique will exclude the ipsilateral supraclavicular fossa, a separate electron field is added (commonly to a depth of 2 to 3 cm depending on the patient&apos;s anatomy) thereby bringing the total dose to 50.4 Gy. For cervical primaries, patients are placed supine. Various field designs are possible and their choice depends on the geometry of the primary tumor in relation to the spinal cord. The ideal design is a three-field technique (two anterior obliques and a posterior). However, since the primary tumor is rarely limited to the midline, the most common approach is anteroposterior (AP)/posteroanterior (PA) to 39.6 to 41.4 Gy (Fig. 36-3) followed by a left or right opposed oblique pair with photons to 50.4 Gy (Fig. 36-4A-C). Since this technique will exclude the ipsilateral supraclavicular fossa, a separate electron field is added (commonly to a depth of 2 to 3 cm depending on the patient&apos;s anatomy) thereby bringing the total dose to 50.4 Gy.
  • Carcinoma oesophagus

    1. 1. Carcinoma EsophagusPresented By:Dr. VandanaDept. of Radiation OncologyCSMMU, Lucknow
    2. 2. Clinical Anatomy„ Hollow muscular tube 25 cm in length which spans from the cricopharyngeus at the cricoid cartilage to gastroesophageal junction (Extends from C7-T10).„ Has 4 constrictions- ƒ At starting(cricophyrangeal junction) ƒ crossed by aortic arch(9’inch) ƒ crossed by left bronchus(11’inch) ƒ Pierces the diaphragm(15’inch)„ Histologically 4 layers: mucosa, submucosa, muscular & fibrous layer. FIGURE Anatomy of the esophagus
    3. 3. Contd…Four regions of the esophagus:„ Cervical = cricoid cartilage to thoracic inlet (15–18 cm from the incisor).„ Upper thoracic = thoracic inlet to tracheal bifurcation (18–24 cm).„ Midthoracic = tracheal bifurcation to just above the GE junction (24–32 cm).„ Lower thoracic = GE junction (32–40 cm). Figure Anatomy of the esophagus with landmarks and recorded distance from the incisors used to divide the esophagus into topographic compartments. GE, gastroesophageal.
    4. 4. Lymphatic Drainage„ Rich mucosal and submucosal lymphatic system.„ The submucosal lymphatics may extend long distances (proximal and distal margins used for RTP have traditionally been a minimum of 5 cm).„ The submucosal plexus drains into the regional lymph nodes in the cervical, mediastinal, paraesophageal, left gastric, and celiac axis regions Figure Lymphatic drainage of the esophagus with anatomically defined lymph node basins
    5. 5. Epidemiology„ Esophageal cancer is the 7th leading cause of cancer deaths.„ accounts for 1% of all malignancy & 6% of all GI malignancy.„ Most common in China, Iran, South Africa, India and the former Soviet Union.„ The incidence rises steadily with age, reaching a peak in the 6th to 7th decade of life.„ Male : Female = 3.5 : 1„ African-American males : White males = 5:1
    6. 6. Contd…„ Worldwide SCC responsible for most of the cases.„ Adenocarcinoma now accounts for over 50% of esophageal cancer in the USA, due to association with GERD , Barretts’s esophagus & obesity.„ SCC usually occurs in the middle 3rd of the esophagus (the ratio of upper : middle : lower is 15 : 50 : 35).„ Adenocarcinoma is most common in the lower 3rd of the esophagus, accounting for over 65% of cases.
    7. 7. Risk Factors : Squamous Cell Carcinoma„ Smoking and alcohol (80% - 90%)„ Dietary factors ƒ N-nitroso compounds (animal carcinogens) ƒ Pickled vegetables and other food-products ƒ Toxin-producing fungi ƒ Betel nut chewing ƒ Ingestion of very hot foods and beverages (such as tea)„ Underlying esophageal disease (such as achalasia and caustic strictures, Tylosis)„ Genetic abnormalities: ƒ p53 mutation, loss of 3p and 9q alleli, amp. Cyclin D1 & amp. EGFR
    8. 8. Risk Factors: Adenocarcinoma„ Associated with Barretts’s esophagus, GERD & hiatal hernia.„ Obesity (3 to 4 fold risk)„ Smoking (2 to 3 fold risk)„ Increased esophageal acid exposure such as Zollinger-Ellison syndrome. Barrett’s esophagus is ametaplasia of the esophageal epithelial lining. Thesquamous epithelium is replaced by columnarepithelium,with 0.5% annual rate of neoplastictransformation. Fig. Barretts’s esophagus
    9. 9. Pattern of spread„ No serosal covering, direct invasion of contiguous structures occurs early.„ Commonly spread by lymphatics (70%)„ Lymph node involvement increases with T stage. ƒ T1 – 14 to 21% ƒ T2 – 38 to 60%„ 25% - 30% hematogenous metastases at time of presentation.„ Most common site of metastases are ƒ lung, liver, pleura, bone, kidney & adrenal gland„ Median survival with distant metastases – 6 to 12 months
    10. 10. Site-wise nodal involvement
    11. 11. Pathological Classification 95%
    12. 12. Clinical Features„ It is commonly associated with the symptoms of dysphagia, wt. loss, pain, anorexia, and vomiting„ Symptoms often start 3 to 4 months before diagnosis„ Dysphagia - in more than 90% pt. Odynophagia - in 50% of pt.„ Wt. loss – more than 5 % of total body wt. in 40 – 70% pt. associated with worst prognosis.
    13. 13. Contd…Complications:„ Cachexia, Malnutrition, dehydration, anaemia,.„ Aspiration pneumonia.„ Distant metastasis.„ Invasion of near by structures: e.g. ƒ Recurrent laryngeal nerve → Hoarseness of voice ƒ Trachea → Stridor & TOF→ cough, choking & cyanosis ƒ Perforation into the pleural cavity → Empyema ƒ back pain in celiac axis node involvement
    14. 14. AJCC TNM classification „ a: Includes nodes previously labeled as “M1a” „ b : “M1a” designation is no longer recognized in the 7th edn. of the AJCC system
    15. 15. Staging : Squamous cell carcinoma
    16. 16. Staging : AdenocarcinomaGroup T N M Grade 0 Tis (HGD) 1, X IA T1 1-2, X IB T1 3 N0 T2 1-2, X IIA T2 3 IIB T3 T1-2 N1 M0IIIA T1-2 N2 T3 N1 T4a N0 AnyIIIB T3 N2IIIC T4a N1-2 T4b Any Any N3 IV Any Any M1
    17. 17. Diagnostic Workup„ Detailed history & Physical examination: Dysphagia, odynophagia, hoarseness, wt. loss, use of tobacco, nitrosamines, history of GERD. Examine for cervical or supraclavicular adenopathy.„ Confirmation of diagnosis: ƒ EGD: allow direct visualization and biopsy, measure proximal & distal distance of tumor from incisor, presence of Barrett’s esophagus. Early, superficial Circumferential ulceration Malignant stricture cancer esophageal cancer of esophagus
    18. 18. „ Staging: ƒ CT chest and abdomen: Essential for staging because it can identify extension beyond the esophageal wall, enlarged lymph nodes and visceral metastases.Figure Esophageal cancer with aortic invasion. An Figure Esophageal cancer with tracheal invasion. CTarc (bent arrow) of the contact between the scan shows circumferential wall thickening of theesophageal cancer (arrows) and the aorta proximal esophagus (arrowheads), which shows(arrowheads) is more than 90 degrees, indicating irregular interface with the posterior wall of the tracheaaortic invasion. (arrows), indicating direct extension into the lumen
    19. 19. Endoscopic Ultrasonography„ EUS: ƒ assess the depth of penetration and LN involvement. Limited by the degree of obstruction. ƒ Compared with EUS, CT is not a reliable tool for evaluation of the extent of tumor in the esophageal wall. Fig. —55-year-old man with T2 esophageal tumor (m) shown on endoscopic sonogram. Note alternating hyperechoic and hypoechoic layers (arrowheads) of normal esophageal wall as seen on sonography. Innermost layer is hyperechoic and corresponds to superficial mucosa. Second layer is hypoechoic and corresponds to deep mucosa and muscularis mucosae. Third layer is again hyperechoic and corresponds to submucosa and its interface with muscularis propria. Fourth layer is hypoechoic and corresponds to muscularis propria, and outer fifth layer is hyperechoic and corresponds to adventitia.
    20. 20. PET Scan „ most recently, proven to be valuable staging tool „ can detect up to 15–20% of metastases not seen on CT and EUS „ low accuracy in detecting local nodal disease compared to CT / EUS „ Value in evaluating response to Chemo Therapy & Radio Therapy „ addition of PET to CT can improve specificity and accuracy of non- invasive stagingFigure Distant lymph node metastases of esophageal cancer detected by integrated CT PET. A, Integrated CTPET demonstrates para-aortic lymph node metastases showing increased FDG uptake (arrowheads). B,Corresponding CT image shows lymph nodes (arrowheads) measuring 5 to 8 mm in diameter. Based on sizecriteria, these lymph nodes may be considered benign on CT scan
    21. 21. „ Barium swallow: ƒ can delineate proximal and distal margins as well as TEF ƒ Helpful for correlation with simulation film.„ Bronchoscopy: rule-out fistula in midesophageal lesions.„ Routine Investigations: CBC, chemistries, LFTs. Cancer lower 1/3 Apple core appearance Rat tail appearance Filling defect (ulcerative type)
    22. 22. Treatment
    23. 23. Management depends upon:„ Site of disease„ Extent of disease involvement„ Co-morbid conditions„ Patient preference.
    24. 24. Surgery„ Prerequisite for surgery ƒ disease should be 5 cm beyond cricophyrangeus.„ Surgery indications ƒ Lower 1/3 rd oesophageal ds involving GE junction. ƒ Tumor size <5 cm . ƒ palliative surgery„ 5-Year OS for surgery alone is 20–25% (no significant difference between surgical techniques according to results of 2 meta-analyses)„ Local failure rate around 19–57% when used alone„ surgical morbidity/mortality related to experience of the surgeons.
    25. 25. Types of Surgery„ Transhiatal esophagectomy: for tumors anywhere in esophagus or gastric cardia. No thoracotomy. Blunt dissection of the thoracic esophagus. Left with cervical anastomosis. Limitations are lack of exposure of midesophagus and direct visualization and dissection of the subcarinal LN cannot be performed.„ Right thoracotomy (Ivor-Lewis procedure): good for exposure of mid to upper esophageal lesions. Left with thoracic or cervical anastomosis.„ Left thoracotomy: appropriate for lower third of esophagus and gastric cardia. Left with low-to-midthoracic anastomosis.„ Radical (en block) resection: for tumor anywhere in esophagus or gastric cardia. Left with cervical or thoracic anastomosis. Benefit is more extensive lymphadenectomy and potentially better survival, but increased operative risk.
    26. 26. Chemotherapy„ No data proving that chemotherapy alone provides improved survival or palliation. Partial response, not long-term remission, is the rule„ Indication ƒ Used in combination with radiation for locally advanced cancers ƒ Used as single treatment modality in stage IV disease ƒ Combination chemotherapy has been used preoperatively in a combined modality approach to esophageal Ca in hopes of controlling occult metastatic disease and improving the resectability rate.
    27. 27. „ Platinum doublet is preferred over single agents„ Cisplatin plus 5-FU or docetaxel are commonly used combinationsRegimens:„ Paclitaxel and carboplatin„ Cisplatin and 5-FU or capecitabine„ Oxaliplatin and 5-FU or capecitabine„ Paclitaxel or docetaxel and cisplatin„ Carboplatin and 5-FU„ Irinotecan and cisplatin„ Oxaliplatin, docetaxel and capecitabine„ Epirubicin, cisplatin and 5-FU (Only for adenocarcinoma)
    28. 28. Radiotherapy„ Curative ƒ Radical RT ƒ Pre-Op RT ƒ Post Op RT ƒ Concurrent chemo-radiation„ Palliative„ EBRT„ Brachytherapy
    29. 29. EBRT Techniques„ Patient Positioning: ƒ CERVICAL ESOPHAGUS: Supine with arms by the side ƒ MID AND LOWER THIRD: ‚ SUPINE With arms above their head if AP – PA portals are being planned ‚ PRONE if posterior obliques are being included. • Esophagus is pulled anteriorly and spinal cord can be spared.„ IMMOBILISATION : ƒ Perspex cast ƒ Vertebral column should be as parallel to couch as possible.„ Barium swallow contrast to delineate the esophageal lumen and stomach.
    30. 30. EBRT – Cervical EsophagusField Portals:„ AP – PA foll. by opposed oblique pair.„ 2 anterior obliques and 1 posterior field.„ 2 posterior obliques and 1 anterior field„ 4 field box with soft tissue compensators foll by obliques ( Univ of Florida tech )„ SUPERIOR BORDER: At C 7„ INFERIOR BORDER : At T 4 ( carina )„ 2 cm lateral margins.„ SC nodes irradiated electively.„ SC nodes will be underdosed if oblique portals are used to treat primary; can be boosted by a separate field if required.
    31. 31. EBRT – Mid & Lower1/3rd AP – PA followed by 1 Ant and 2 Post oblique pair 4 FIELD : AP-PA & opposed laterals – for mid 1/3rd lesions with patient in prone position. AP-PA upto 43 Gy foll by 2 Post obliques upto 50 Gy ( gross disease boosted to 60 Gy )„ SUPERIOR BORDER: 5 cm proximal to superior extent of disease.„ INFERIOR BORDER: ƒ MID 1/3RD – AT GE jn. As visualised by Barium swallow ƒ LOWER 1/3RD - Coeliac plexus ( L 1 ) to be included.
    32. 32. Radiotherapy for CA esophagus
    33. 33. EBRT - DOSES„ Energy ƒ 6 – 10 MV linac or Co60„ Chemoradiation: ƒ 50.4 Gy in 28 # at 1.8 Gy per # ƒ Boost to 60 – 66 Gy for residual disease„ Radical RT: ƒ 45 Gy / 25 # / 1.8 Gy per # ƒ boost with 2 cm margin to total dose of 60Gy„ Dose limitations ƒ Spinal cord Dmax:45 Gy at 1.8 Gy/fx ƒ Lung: Limit 70% of both lungs <20 Gy ƒ Heart: Limit 50% of ventricles <25 Gy
    34. 34. Brachytherapy (Intraluminal)„ As a boost after EBRT or as a palliative measure„ Local control of 25% - 35 in palliative setting„ In curative setting, addition of brachytherapy does not improve results compared to Chemoradiation.„ Limit dose to critical structure„ Dose escalation to primary„ Relief bleeding, pain and improves swallowing status in palliative setting.
    35. 35. American Brachytherapy Society GuidelinesPatient selection: ƒ Primary tumor length ≤ 10 cm length ƒ Tumor confined to esophageal wall ƒ Thoracic esophagus location ƒ No nodal / systemic metastasis.Contraindications: ƒ T E fistula ƒ Cervical esophagous location ƒ Stenosis which cannot be bypassed
    36. 36. Contd…„ EBRT 45 – 50 Gy in 1.8-2.0Gy /#,5#/wk ‚ HDR – 5 Gy x two # one week apart , 2 – 3weeks after EBRT. ‚ LDR – single 20 Gy # @ 0.4 – 1.0 Gy per hr, 2 -3 weeks after EBRT.„ Never concurrently with chemotherapy„ Ext diameter of applicator must be 6 – 10 mm.„ Active length : visible tumor by UGI scopy plus 1 – 2 cm proximal & distal margin.„ Dose is prescribed 1 cm from mid source or mid dwell position.
    37. 37. APPLICATORS
    38. 38. Trials – RT alone„ No randomized trials of RT Vs Sx„ 5 yr survival with conventional RT : < 10%„ Tumors < 5 cm , 5 yr survival : 20%„ Stage wise 5 yr survival: ƒ Stage I – 20% ƒ Stage II – 10% ƒ Stage III – 3 % ƒ Stage IV – 0%
    39. 39. Contd…„ For cervical esophagus, cure rates were similar with Radical RT or Sx alone.„ RT or Sx alone DOES NOT alter the natural history of the disease.„ RTOG 8501: RT Vs Chemo RT ƒ Better LRC and improved OS with ChemoRT RT alone should be used for palliation or in medically unfit patients.
    40. 40. Trials– PreOP RT„ Principle: ƒ ↑ resectability, ↓ likelihood of tumor dissemination during Sx , ↑ radioresponsiveness due to unaltered blood supply ƒ 5 randomised trials ,shows no apparent clinical benefit to use of preop rt alone except, ƒ Only one trial ( Huang et al ) showed survival advantage of 46% Vs 25% with 40 Gy RT ƒ Recent meta analysis Oesophageal Cancer Collaborative Group study showed no clear survival advantage. No difference in resectability rates, LRC or survival with pre-op RT
    41. 41. Trials– PostOP RT„ Advantages: ƒ Treat areas at risk for recurrences while minimizing dose to OAR. ƒ Patients with node negative , completely resected T1 / T2 tumors can be excluded.„ Disadvantage: ƒ Tolerance of stomach or bowel used for interpositioning.
    42. 42. Contd…„ 2 randomised trials: ƒ Peniere et al :- ‚ 221 pts, mid / low 1/3rd growth ‚ RT : 45- 55 Gy @ 1.8 Gy per # ‚ 3 yrs -  local failure rate ( from 35% to 10%) - no significant disease free survival. ƒ Fok et al :- ‚ 130 pts , RT – 49 Gy @ 3.5 Gy per # ‚ Local failure rate  in patients who had palliative resection ( from 46% to 20% ) ‚ No difference for completely resected patients Post op RT improves local control, but does not confer any survival advantage.
    43. 43. Trials– Chemoradiation ChemoRT Vs RT Alone„ RTOG 8501 INTERGROUP TRIAL: ƒ 121 pts: 60 pts RT alone – 64 Gy @ 2 Gy per # 61 pts chemoRT – 50 Gy RT + 5 FU + CDDP – on 1 , 5 , 8 & 11 weeks ƒ Median survival : 8.9 Vs 12.5 months ƒ 5 yr survival : 0% Vs 30 % ƒ Distant mets @ 5 yrs: 40% Vs 12 % ƒ Acute toxicity : 25% Vs 44 %„  Median & overall survival, LRR and Acute toxicity in Chemo RT arm. Chemoradiation is a standard Non-surgical Tx.
    44. 44. Contd… RT dose escalation in Chemo RT„ Intergroup 0123 TRIAL – 218 pts ƒ Chemoradiation - either 50.4 Gy or 64.8 Gy ƒ No significant difference in median survival, 2 yr survival or loco- regional failure. Intensification of RT dose beyond 50.4 Gy(in combination with chemotherapy ) does not improve results.
    45. 45. Contd… PRE OP CHEMO RT Vs Sx ALONE„ 44 Randomised trials„ 2 studies showed  in local recurrence ƒ Urba et al – 19 % Vs 42 % ƒ Bosset et al ( EORTC ) – 28% Vs 40%„ One study showed significant survival benefit at 3 yrs (in pts who had a pathologic CR ) ƒ Urba et al – 64% Vs 19%„ One study (Walsh et al) showed benefit in median (16 Vs 11 months ) and overall survival at 3 yrs ( 32 Vs 6%) Results support TRIMODALITY approach.
    46. 46. Pre-operative Chemotherapy The role of preoperative chemotherapy alone is controversial, according to mixed results from clinical trials.
    47. 47. Stage Recommended treatmentStage I–III and IVA definitive chemo-RT (preferred for cervical esophagus)resectablemedically-fit Or, Pre-op chemo-RT → surgery. Surgery preferred for adenocarcinoma regardless of response to chemo-RT. Or, surgery. (noncervical T1N0 and young T2N0 patients with primaries of lower esophagus or gastroesophageal junction. Indications for post-op chemo-RT include: unfavorable T2N0, T3/4, LN+, and/or close/+ margin.Stage I–III inoperable Definitive chemo-RTStage IV palliative Concurrent chemo-RT (5-FU + cisplatin, 50 Gy) or RT alone (e.g., 2.5 Gy × 14 fx) or chemo alone or best supportive care. Pain: medications ± RT Bleeding: endoscopic therapy, surgery, or RT
    48. 48. Current approach„ EBRT using 3D-CRT to a total dose of 50.4 Gy (1.8 Gy per daily fraction) is standard.„ IMRT is often utilized to minimize exposure to adjacent structures.„ Proton beam in combination with chemotherapy is being explored.„ Targeted biologic agents added to standard cytotoxic chemotherapy is being explored
    49. 49. Conclusion„ Esophageal cancer is the 7th leading cause of cancer deaths.„ Adenocarcinoma now accounts for over 50% of esophageal cancer in the USA, due to association with GERD & obesity.„ Dysphagia and weight loss are the two most common presentations in patients with esophageal cancer.„ Endoscopic ultrasound (EUS) is necessary to accompany a complete workup for proper staging and diagnosis of esophageal cancer.„ Surgery is the standard of care for early-stage esophageal cancer.„ Preoperative chemotherapy and radiation is the standard option for locally advanced esophageal cancer in surgically eligible patients.
    50. 50. Thank You
    51. 51. ChemoRT followed Sx Vs.ChemoRT „ Patient undergoing surgery have worse quality of life. „ Surgery following combined CRT appears to improve local control, its impact on ultimate survival remains controversial.
    52. 52. Figure: A proposed treatmentalgorithm for esophageal cancer.
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×